European Commission approval for 320 mg device presentations of Bimzelx (bimekizumab) – UCB
UCB, a global biopharmaceutical company, announced that the European Commission (EC) has granted marketing authorization for two 320 mg device presentations of Bimzelx (bimekizumab). The pre-filled syringe and… read more.